CG Oncology Inc. (CGON), a late-stage clinical biopharmaceutical company developing a bladder-sparing therapeutic for patients with bladder cancer, has high-stakes catalysts to watch in the coming months.
The company's product candidate is Cretostimogene grenadenorepvec, an engineered oncolytic immunotherapy, whose lead indication is for high-risk Non-Muscle Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin (BCG) therapy with carcinoma in situ (CIS) with or without Ta or T1 disease. It is administered intravesically, meaning delivered directly into the bladder through a catheter.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.